CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
04 nov. 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics to Present at Upcoming Investment Conferences
03 nov. 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
01 nov. 2022 08h01 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
03 oct. 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
14 sept. 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
Redefining Expectations for PBC Patients September 22, 2022 at 10:30 AM ET NEWARK, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage...
CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h02 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
24 août 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
11 août 2022 16h05 HE
|
CymaBay Therapeutics, Inc.
Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) --...
CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
04 août 2022 16h05 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
01 août 2022 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...